BIOMAT Database Logo BIOMAT Database Logo

[Pathogenesis of tolylene diisocyanate intoxication]. 2000

T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ

Experimental and clinical investigations to evaluate immunity, lipid peroxidation (LPO), and antioxidative defense (AOD) under the action of tolylene diisocyanate at the level of MAC and 10 MAC were conducted for further studies of the agent's pathogenetic mechanisms. The experimental investigations showed the predominant activation of cellular and humoral immunities, as well as the suppression of nonspecific defence at 10 MAC, enhanced LPO, and phasic changes in AOD. Most profound immunological changes were observed in those having as long as 5 years of length of service.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D008297 Male Males
D008452 Maximum Allowable Concentration The maximum exposure to a biologically active physical or chemical agent that is allowed during an 8-hour period (a workday) in a population of workers, or during a 24-hour period in the general population, which does not appear to cause appreciable harm, whether immediate or delayed for any period, in the target population. (From Lewis Dictionary of Toxicology, 1st ed) Maximum Permissible Exposure Level,MPEL,Maximum Permissible Exposure Concentration,Allowable Concentration, Maximum,Allowable Concentrations, Maximum,Concentration, Maximum Allowable,Concentrations, Maximum Allowable,MPELs,Maximum Allowable Concentrations
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009784 Occupational Diseases Diseases caused by factors involved in one's employment. Diseases, Occupational,Occupational Illnesses,Disease, Occupational,Illnesse, Occupational,Illnesses, Occupational,Occupational Disease,Occupational Illnesse
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Toluene diisocyanate (tolylene diisocyanate, TDI).
January 1967, American Industrial Hygiene Association journal,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Asthmatic syndrome following exposure to tolylene diisocyanate.
November 1956, Industrial medicine & surgery,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
The effect of tolylene diisocyanate on certain laboratory animals.
April 1970, Proceedings of the Royal Society of Medicine,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Contact sensitivity in mice induced by tolylene diisocyanate (TDI).
August 1980, The Journal of dermatology,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Contact sensitivity in rats induced by tolylene diisocyanate (TDI).
December 1985, The Journal of dermatology,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Immune responses to tolylene diisocyanate (TDI) exposure in man.
April 1970, Proceedings of the Royal Society of Medicine,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Lung function of men engaged on the manufacture of tolylene diisocyanate (TDI).
April 1970, Proceedings of the Royal Society of Medicine,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Symptoms and lung function following acute and chronic exposure to tolylene diisocyanate.
April 1970, Proceedings of the Royal Society of Medicine,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Specific inhibition of contact sensitivity in the guinea pig following tolylene diisocyanate inhalation.
January 1982, International archives of allergy and applied immunology,
T V Osipova, and A V Litovskaia, and T V Vasil'eva, and I V Egorova, and T Iu Feklina, and A B Vifleemskiĭ
Use of tolylene diisocyanate for the preparation of a peroxidase-labelled antibody conjugate. Quantitation of the amount of diisocyanate bound.
January 1973, Biochimica et biophysica acta,
Copied contents to your clipboard!